Experimental INKmune therapy for blood cancers halted after just 2 patients

NCT ID NCT05933070

Terminated Disease control Sponsor: Inmune Bio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested an experimental drug called INKmune in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal was to find a safe dose and check for side effects. However, the study was stopped early after only 2 people enrolled, so no clear conclusions can be drawn.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia cancer myelodysplastic syndrome myelodysplastic syndrome with excess blasts Myelodysplastic Syndromes neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA AML CANCER MDS-EB MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

Attikon University General Hospital

Athens, Attica, 124 62, Greece
Sheffield Teaching Hospitals NHS FT - Royal Hallamshire Hospital

Sheffield, Sheffield, S10 2RX, United Kingdom
University Hospital Southampton NHS Foundation Trust

Southampton, Hampshire, S016 6YD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.